Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis

Panunzio, Andrea; Tafuri, Alessandro; Mazzucato, Giovanni; Cerrato, Clara; Orlando, Rossella; Pagliarulo, Vincenzo; Antonelli, Alessandro; Cerruto, Maria Angela

doi:10.3390/toxins14010025

Cited by 15 publications

(8 citation statements)

References 32 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 (7) Botulinum toxin A may represent a promising therapeutic strategy for these patients. 58 Botulinum toxin can inhibit the release of acetylcholine from nerve fiber endings, which determines a transient skeletal muscle relaxation and produces an analgesic effect by reducing muscle hyperactivity. 59 The etiology of both diseases is not fully understood, but infection, immunity, inflammation, and psychosomatic factors are common influences in both.…”

Section: Medicationmentioning

confidence: 99%

A Bibliometric Analysis of Urologic Chronic Pelvic Pain Syndrome From 2000 to 2022

Wang¹,

Cao²,

Lin³

et al. 2023

JPR

View full text Add to dashboard Cite

Urologic chronic pelvic pain syndrome has attracted a lot of attention in the new century, and an increasing number of relevant studies have been published. Therefore, we performed a bibliometric analysis of these publications, hoping to show the current research hotspots and future research trends. Methods: The articles on were selected from the Web of Science Core Collection. Countries, authors, references and keywords in the field were visualized and analyzed using CiteSpace and VOSViewer software. Results: A total of 1014 articles on urologic chronic pelvic pain syndrome were identified, with "chronic pelvic pain syndrome" being the most common keyword, with a strong association with "interstitial cystitis" and "chronic prostatitis". The hotspot of urologic chronic pelvic pain syndrome research has gradually shifted from chronic prostatitis / urologic chronic pelvic pain syndrome to cystitis/bladder pain syndrome over the past few years. Future research tends to focus on urologic chronic pelvic pain syndrome etiology, including oxidative stress and inflammation. Conclusion:Research on urologic chronic pelvic pain syndrome is steadily growing. The United States has made the most prominent contribution in this area, and the share of China's contribution is expected to grow further. The etiology of urologic chronic pelvic pain syndrome, including inflammation and oxidative stress, have been the focus of current research and developmental trends in the future research.

show abstract

Section: Medicationmentioning

confidence: 99%

A Bibliometric Analysis of Urologic Chronic Pelvic Pain Syndrome From 2000 to 2022

Wang¹,

Cao²,

Lin³

et al. 2023

JPR

View full text Add to dashboard Cite

show abstract

“…Botulinum neurotoxin A (BTX-A) was proven effective in improving the symptoms that afflicted IC/BPS patients in several meta-analyses [ 91 , 92 , 93 , 94 ]. Furthermore, compared to hydrodistension alone, the sequential therapy of hydrodistension and intravesical injection of BTX-A (200/100 U) was significantly more efficacious in increasing bladder capacity and alleviating pain than hydrodistension alone at three months (all p < 0.05), and the success rates in a global response assessment (GRA) were also higher at 24 months ( p = 0.007) [ 95 ].…”

Section: Treatment Of Ic/bpsmentioning

confidence: 99%

Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome

2022

IJMS

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating disease that induces mental stress, lower urinary symptoms, and pelvic pain, therefore resulting in a decline in quality of life. The present diagnoses and treatments still lead to unsatisfactory outcomes, and novel diagnostic and therapeutic modalities are needed. Although our understanding of the etiology and pathophysiology of IC/BPS is growing, the altered permeability of the impaired urothelium, the sensitized nerves on the bladder wall, and the chronic or intermittent sensory pain with inaccurate location, as well as pathologic angiogenesis, fibrosis, and Hunner lesions, all act as barriers to better diagnoses and treatments. This study aimed to summarize the comprehensive information on IC/BPS research, thereby promoting the progress of IC/BPS in the aspects of diagnosis, treatment, and prognosis. According to diverse international guidelines, the etiology of IC/BPS is associated with multiple factors, while the presence of Hunner lesions could largely distinguish the pathology, diagnosis, and treatment of non-Hunner lesions in IC/BPS patients. On the basis of the diagnosis of exclusion, the diverse present diagnostic and therapeutic procedures are undergoing a transition from a single approach to multimodal strategies targeting different potential phenotypes recommended by different guidelines. Investigations into the mechanisms involved in urinary symptoms, pain sensation, and bladder fibrosis indicate the pathophysiology of IC/BPS for further potential strategies, both in diagnosis and treatment. An overview of IC/BPS in terms of epidemiology, etiology, pathology, diagnosis, treatment, and fundamental research is provided with the latest evidence. On the basis of shared decision-making, a multimodal strategy of diagnosis and treatment targeting potential phenotypes for individual patients with IC/BPS would be of great benefit for the entire process of management. The complexity and emerging evidence on IC/BPS elicit more relevant studies and research and could optimize the management of IC/BPS patients.

show abstract

“…The management of CPPS is based on a biopsychosocial model, which includes active patient involvement. Pharmacological and nonpharmacological interventions, such as psychotherapy, physiotherapy, drugs, botulinum toxin injection, and phytotherapy, often need to be considered together as a part of a multimodal and personalized treatment strategy [1,8,9]. Considering phytotherapy, in recent years, hempseed oil and derivates and maritime pine bark dry extract have been suggested to have important nutrition benefits for humans and useful analgesic properties.…”

Section: Introductionmentioning

confidence: 99%

Micronized Palmitoylethanolamide, Hempseed Oil, and Maritime Pine Bark Dry Extract (Pelvipea®) for Pelvic Pain: An In Vitro Study for Urothelial Inflammation Treatment

Tafuri

Panunzio

Mitri

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

Urothelial inflammation plays a key role in the pathogenesis of chronic pelvic pain due to its origin in the bladder. The aim of this study was to evaluate the efficacy of a patent-pending formulation (Pelvipea®) composed of micronized palmitoylethanolamide (PEA), hempseed oil, and maritime pine bark dry extract in reducing urothelial inflammation, as well as the effect of each ingredient individually, in order to define the synergistic effect of the three ingredients. An in vitro bladder urothelium model composed of the T24 cell line was exposed to a conditioned media obtained by treating macrophage-differentiated THP-1 cells with different concentrations of the functional ingredients and a mixture of them in the presence of the pro-inflammatory stimulus of Escherichia coli. Cells exposed only to the inflammatory stimulus in the absence of pre-treatment were considered as a positive control for inflammation. The impact of each functional ingredient and their mixture on inflammation was evaluated by the determination of transcription factor NF-kB and of pro-inflammatory cytokine expression. Statistical analysis was performed using the t-test, comparing the mixture and the single ingredients for every condition tested. All results were reported as fold change (mean ± standard deviation), the ratio between the values obtained from the respective treatments for inflammation control. The three functional ingredients did not induce negative effects on THP-1 cell vitality. The levels of NF-kB were reduced following treatment with hempseed oil, maritime pine bark dry extract, and the mixture at all tested concentrations, and with micronized PEA from 25 to 200 μg/mL. Treatment with the mixture resulted in the lowest expression levels of interleukins (IL)-1β, IL-6, and IL-8 compared to the single functional ingredients at a concentration of 230 μg/mL, with values of 0.08 (±0.00), 0.01 (±0.00), and 0.32 (±0.01), respectively. The mixture of micronized PEA, hempseed oil, and maritime pine bark dry extract (Pelvipea®) at 230 μg/mL showed the best efficacy in urothelial IL-1β, IL-6, and IL-8 reduction compared with the singular components. This formulation may represent a promising therapeutic option to relieve painful symptoms originating in the bladder. However, in vivo studies are needed to confirm these results.

show abstract

Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis

Cited by 15 publications

References 32 publications

A Bibliometric Analysis of Urologic Chronic Pelvic Pain Syndrome From 2000 to 2022

A Bibliometric Analysis of Urologic Chronic Pelvic Pain Syndrome From 2000 to 2022

Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome

Micronized Palmitoylethanolamide, Hempseed Oil, and Maritime Pine Bark Dry Extract (Pelvipea®) for Pelvic Pain: An In Vitro Study for Urothelial Inflammation Treatment

Contact Info

Product

Resources

About